ACET's Business Model
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
| Sector & Industry | Healthcare / Biotechnology |
| Website | https://www.adicetbio.com |
| CEO (Chief Executive Officer) | Chen Schor |
| Number of Employees | |
| IPO date | January 26, 2018 |
ACET Latest News
|
|
|
|
|
|
|
|
|
|
| Contact | |
|---|---|
| Country | US |
| Address | 200 Clarendon Street |
| City | Boston |
| State | MA |
| Phone | 650 503 9095 |
| Zip Code | 02116 |
| Other Identifiers | |
| CIK | 0001720580 |
| ISIN | US0070022076 |
| CUSIP | 007002108 |
| Open | 6.76 |
| Previous Close | 6.72 |
| Volume | 108.9 Thou. |
| Average Volume | 183.8 Thou. |
| Day’s Range | 6.72 – 7.28 |
| 52 Week Range | 6.407-17.44 |
| MA (50) | 8.02908 |
| MA (200) | 10.82031 |
| Market Cap | 69.54 Mil. |
| Shares Out. | 9.58 Mil. |
| Earnings Date | Mar 05, 2026 |
| Beta | |
| Last Dividend | |
| EPS | |
| PE | |
Industry Competitors for ACET
|
Company
|
PE Ratio | Market Cap |
|---|---|---|
|
|
||
|
|
||
|
|
||
|
|
||
|
|
||
|
|
||
|
|
||
|
|
||
|
|
||
|
|
